Hepatitis C infection and chronic kidney disease among Hispanics/Latinos

Eugenia Wong1, Ana C Ricardo2, Sylvia E Rosas3

  • 1Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Medicine
|December 10, 2021
PubMed

Insights

Hepatitis C virus (HCV) infection is not strongly linked to new chronic kidney disease (CKD) in Hispanics/Latinos. While HCV+ individuals showed faster eGFR decline, it did not translate to increased CKD incidence in this cohort.

Area of Science:

  • Nephrology
  • Infectious Diseases
  • Epidemiology

Background:

  • Hepatitis C virus (HCV) infection can lead to secondary kidney diseases.
  • HCV is a potential risk factor for chronic kidney disease (CKD), but data in Hispanic/Latino populations is limited.

Purpose of the Study:

  • To investigate the association between HCV infection and the incidence of CKD among Hispanics/Latinos.
  • To analyze the impact of HCV on estimated glomerular filtration rate (eGFR) and albuminuria.

Main Methods:

  • Prospective cohort study of 10,430 Hispanics/Latinos from the Hispanic Community Health Study/Study of Latinos.
  • HCV+ defined by antibody and RNA/recombinant immunoblot assay testing.
  • Incident CKD defined by eGFR <60 mL/min/1.73 m² or albuminuria thresholds; Poisson and linear regression used for analysis.

Main Results:

  • Over 5.9 years, 712 incident CKD events occurred.
  • HCV+ was not associated with incident CKD (IRR 1.29).
  • HCV+ was associated with higher eGFR risk stages (IRR 2.39) and a faster annualized eGFR decline (-0.69 mL/min/m²/year).

Conclusions:

  • This study found no strong evidence linking HCV infection to new-onset CKD in the Hispanic/Latino population.
  • HCV infection may not significantly increase CKD risk in this demographic.
  • Direct-acting antiviral treatment is recommended for all HCV+ individuals, irrespective of kidney disease status.

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
104
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
143
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
134
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
17
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
390
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
18